MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
83.73
+0.08
+0.10%
After Hours: 83.72 -0.01 -0.01% 19:34 07/24 EDT
OPEN
83.75
PREV CLOSE
83.65
HIGH
83.80
LOW
83.68
VOLUME
2.34M
TURNOVER
--
52 WEEK HIGH
84.00
52 WEEK LOW
25.83
MARKET CAP
8.86B
P/E (TTM)
-16.3118
1D
5D
1M
3M
1Y
5Y
1D
Catalyst Watch: Tech majors report, FOMC, Jersey Mike's IPO and more oil anxiety
Seeking Alpha · 1d ago
Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor
TipRanks · 2d ago
Biotech stocks lead healthcare's overbought list as earnings picks up
Seeking Alpha · 2d ago
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
TipRanks · 3d ago
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Benzinga · 4d ago
Weekly Report: what happened at CRNX last week (0713-0717)?
Weekly Report · 5d ago
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
The Motley Fool · 6d ago
Google, Tesla, Intel To Headline Earnings Next Week
Seeking Alpha · 07/18 15:00
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.